Chief Scientific Officer
King Of Prussia, PA, USA | Beyond Spring Pharma
Industry:Pharmaceutical / Biotech
Job Description:60 people have viewed this job
A Chief Science Officer (CSO) to provide scientific vision and leadership to Seed Therapeutics’ discovery and nonclinical development efforts. The CSO will spearhead Seed’s global strategy of discovering and developing novel molecular glue-based targeted protein degradation (TPD) therapies. Reporting to the CEO, and as a member of the Seed Executive Leadership, the CSO will play a key strategic role in setting and achieving the scientific goals of Seed, including discovery and nonclinical development. The CSO provides a focus on successful “bench to bedside” drug development, including platform technology development and deployment, disease indication selection, novel agent discovery, and mechanism of action (MOA) studies. S/he will help identify, recruit, and guide top academic collaborators for sponsored scientific research efforts aimed at furthering Seed’s strategic scientific goals. The CSO will also lead Seed’s efforts to secure additional rounds of funding to advance nonclinical and eventually clinical research efforts.
Build and lead Seed Therapeutics’ drug discovery pipeline centered on molecular glue based targeted protein degradation strategies
Drive novel research that explores and elucidates novel drug(s) mechanisms of action.
Recruit, mentor and develop a team of innovative scientists and drug development professionals.
Establish nonclinical research budgets and work with the leadership team to gain budget approval. Oversee the approved budget for assigned activities.
Advance Seed nonclinical projects from early discovery through successful IND filing.
Interact with BeyondSpring groups, including clinical, regulatory, commercial and finance functions
Ensure and regularly communicate to company leadership, a well-rounded and scientifically rigorous review of the company’s drug development pipeline.
Oversee the identification of contract research organizations (CROs) to perform nonclinical research, maintain the integrity, utility and completeness of the reports finalized for each study.
Establish, oversee, and guide academic groups performing sponsored nonclinical research to achieve scientific goals and peer-reviewed publications.
Perform scientific due diligence on in-licensing and partnering opportunities.
Represent Seed Therapeutics at scientific and industry meetings and describe the company's strategy and pipeline research to internal and external stakeholders including scientific peers, potential investors, partners, collaborators, and regulatory agencies.
Publish peer-reviewed manuscripts with Seed generated data, in support of nonclinical research and drug development efforts.
Remain current on industry trends and advise the organization regarding scientific matters.
Lead consultants within specific scientific areas
Perform other duties as assigned or special projects as needed
Required Qualifications for Consideration Are…
PhD in life sciences, chemistry or other drug discovery related areas.
A minimum of 15 years of industry experience accompanied by progressive responsibility/authority in biopharma R&D management.
Extensive experience across multiple therapeutic areas (with particular emphasis on oncology and CNS disease) and a solid track record of publications.
Experience in targeted protein degradation and/or the ubiquitin proteasome system preferred.
Strong background in molecular/cellular pharmacology, and a track record of progressing compounds from discovery to development is preferred.
Strong leadership skills and excellent interpersonal and emotional intelligence.
Independent and imaginative thinker who can be flexible enough not only to lead a big vision strategy, but also be willing to roll up sleeves in a startup environment.
Ability to facilitate creative and collegial group dynamics and a capacity to influence others at all levels.
Prior experience interacting with clinical development teams a plus.
A key participant in business development; must be familiar with market/opportunity analysis.
Outstanding presentation skills and an ability to effectively communicate program progress/challenges to management, partners, investors, and to scientific audiences.
Proven ability to develop appropriately aggressive milestones and consistently achieve/over achieve targets.
Experience filing the nonclinical sections of an IND and NDA a plus.
Ability to travel domestically/internationally up to 20% of the time.
Already a member? Sign In